WT1 Peptide
Wilms Tumor Protein 1 Peptide Vaccine
Peptide fragments derived from the Wilms tumor protein 1 (WT1) used in cancer immunotherapy vaccines to stimulate cytotoxic T-lymphocyte responses against WT1-overexpressing tumors including leukemia, mesothelioma, and solid tumors.
Mechanism of Action
WT1 peptides are presented by MHC class I molecules on antigen-presenting cells, activating CD8+ cytotoxic T-lymphocytes that recognize and kill WT1-overexpressing cancer cells. Various HLA-restricted peptides (e.g., WT1-126, WT1-235) have been developed for different patient populations.
Health Claims & Evidence
Induces WT1-specific cytotoxic T-cell responses
Reduces minimal residual disease in AML
Extends progression-free survival in mesothelioma
Short-Term Effects
Injection site reactions, mild flu-like symptoms from immune activation.
Long-Term Effects
Sustained WT1-specific T-cell immunity in responders.
Side Effects
Injection site reactions, fatigue, fever. Rare autoimmune reactions.
Contraindications
Active autoimmune disease. Use only under oncologist supervision.
This profile is provided for educational research only. It is not a treatment recommendation or dosing guide. Human evidence, safety information and regulatory status vary by substance. Verify primary sources and consult a qualified healthcare professional for medical decisions.
Research Papers
WT1 peptide vaccine in AML
Oka et al. · Journal of Clinical Oncology · 2004
Educational research only. This profile is not a treatment recommendation or dosing guide. Human evidence, safety information and regulatory status vary by substance. Consult a qualified healthcare professional for medical decisions.
Related Peptides
Explore the research further
Our AI Research Advisor can help you explore the evidence on WT1 Peptide and related peptides, and prepare an educational research summary.
Explore Research